title: Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
abstract: Forty-six patients with refractory solid malignancies received the new platinum complex [2,2-bis(aminomethyl)-1,3-propanediol-N-N'] [1,1-cyclobutanedicarboxylato] [(2-)0,0')] platinum (zeniplatin). Zeniplatin was given, without hydration or mannitol, as a 60- to 90-min i.v. infusion every 3 weeks at doses ranging from 8 to 145 mg/m2. The maximum tolerated dose of zeniplatin was 145 mg/m2. The dose-limiting toxicity of zeniplatin was dose-related leukopenia and neutropenia, with the nadir usually observed between 1 and 2 weeks after therapy and recovery usually occurring by 3 weeks after therapy. Thrombocytopenia was rare. The most prominent non-hematological side-effect of zeniplatin was nausea and vomiting. Other non-hematological side-effects were mild or absent. Zeniplatin did not induce significant neurological or auditory toxicity. Zeniplatin was not nephrotoxic at doses less than or equal to 120 mg/m2. At 145 mg/m2, the clearance decreased by a mean of 40% after 2 cycles of therapy. Two patients, one with malignant melanoma and one with renal cell cancer, achieved a partial response. Pharmacokinetics of free (plasma ultrafiltrates) and total platinum in plasma were determined in 5 patients. An in vitro study of the rate and extent of zeniplatin binding to protein in human plasma was also performed. Free and total platinum were measured by flameless atomic absorption spectrometry; free zeniplatin was measured in ultrafiltrate by HPLC. Total and free plasma platinum concentrations were co-modelled using the information from the in vitro study.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institut Jules Bordet, Brussels, Belgium.
authors.forename: P F
authors.initials: PF
authors.lastname: Dodion
authors.forename: D
authors.initials: D
authors.lastname: de Valeriola
authors.forename: N
authors.initials: N
authors.lastname: Crespeigne
authors.forename: J D
authors.initials: JD
authors.lastname: Kantrowitz
authors.forename: M
authors.initials: M
authors.lastname: Piccart
authors.forename: F
authors.initials: F
authors.lastname: Wery
authors.forename: J
authors.initials: J
authors.lastname: Kerger
authors.forename: M J
authors.initials: MJ
authors.lastname: Egorin
authors.forename: A
authors.initials: A
authors.lastname: Forrest
authors.forename: N R
authors.initials: NR
authors.lastname: Bachur
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D016190:Carboplatin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000473:pathology; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia
chemical_list: D000970:Antineoplastic Agents; C060594:zeniplatin; D016190:Carboplatin